Results 51 to 60 of about 10,004,929 (375)

Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

The Journal of the National Comprehensive Cancer Network, 2021
The NCCN Guidelines for Hepatobiliary Cancers focus on the screening, diagnosis, staging, treatment, and management of hepatocellular carcinoma (HCC), gallbladder cancer, and cancer of the bile ducts (intrahepatic and extrahepatic cholangiocarcinoma ...
A. Benson, M. D'Angelica, D. Abbott, D. Anaya, R. Anders, C. Are, Melinda Bachini, M. Borad, Daniel B. Brown, Adam M. Burgoyne, P. Chahal, D. Chang, J. Cloyd, A. Covey, E. Glazer, L. Goyal, W. Hawkins, R. Iyer, R. Jacob, R. Kelley, R. Kim, M. Levine, M. Palta, James O. Park, S. Raman, S. Reddy, V. Sahai, T. Schefter, Gagandeep Singh, S. Stein, J. Vauthey, A. Venook, A. Yopp, Nicole R Mcmillian, Cindy Hochstetler, S. Darlow   +35 more
semanticscholar   +1 more source

Using of Binominal Method for the Purpose of Determination of Confidence Intervals for Prediction of Invasive Ductal Breast Carcinoma Metastases [PDF]

, 2016
The study was performed using surgical and biopsy material based on histopathological study, which was conducted at the Chernivtsy Regional Clinical Oncology Centre.
Davydenko, I. (Igor), Lazaruk, A. (Alexandr)   +1 more
core   +2 more sources

Clinical trials in oncology

Medicine, 2008
The development of a new treatment in cancer generally involves its assessment in Phase I, II and III prospective clinical trials. This article gives an overview of these phases of clinical trial, through which almost every new treatment will need to pass on the journey from its discovery on the laboratory bench to its routine use in clinical practice.
openaire   +6 more sources

Glucocorticoids in clinical oncology

Cleveland Clinic Journal of Medicine, 1992
Glucocorticoids have been used in clinical oncology for more than three decades. Their anti-inflammatory action plays a major role in their clinical applications in oncology. The incidence and severity of side effects depend on the total dose and the duration of therapy, but optimal dosages for these drugs have not been determined.
Declan Walsh, Jay Avashia
openaire   +3 more sources

Attitudes of advanced Australian medical oncology trainees to rural practice [PDF]

, 2008
Aim: To identify the views of medical oncology trainees regarding rural training posts and rural practice overall, and to identify factors that may improve recruitment. Methods: A questionnaire was posted to all advanced oncology trainees in Australia
Clarke, Kerrie A., Francis, Heather Marion, Francis, Jillian Joy, Steer, Christopher B., Underhill, Craig R.   +4 more
core   +1 more source

Enrollment of adolescents and young adults onto SWOG cancer research network clinical trials: A comparative analysis by treatment site and era. [PDF]

, 2020
BackgroundFew adolescents and young adults (AYAs, 15-39 years old) enroll onto cancer clinical trials, which hinders research otherwise having the potential to improve outcomes in this unique population.
Blanke, Charles, Budd, Troy, Freyer, David R, Johnson, Rebecca H, Lewis, Mark A, O'Mara, Ann M, Pollock, Brad H, Roth, Michael E, Unger, Joseph M   +8 more
core   +2 more sources

American Society of Clinical Oncology Policy Statement on Clinical Pathways in Oncology [PDF]

Journal of Oncology Practice, 2016
The use of clinical pathways in oncology care is increasingly important to patients and oncology providers as a tool for enhancing both quality and value. However, with increasing adoption of pathways into oncology practice, concerns have been raised by ASCO members and other stakeholders.
Dana S. Wollins, James N. Frame, Linda D. Bosserman, Steven K. Stranne, Robin Zon, Michael N. Neuss, Ray D. Page   +6 more
openaire   +3 more sources

Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology.

The Journal of the National Comprehensive Cancer Network, 2022
The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to provide guidance on the management of immune-related adverse events resulting from cancer immunotherapy. The NCCN Management of Immunotherapy-Related Toxicities Panel
John A Thompson, B. Schneider, J. Brahmer, Amaka Achufusi, Philippe Armand, Meghan K Berkenstock, S. Bhatia, L. Budde, S. Chokshi, M. Davies, Amro Elshoury, Yaron Gesthalter, A. Hegde, M. Jain, B. Kaffenberger, M. Lechner, Tianhong Li, A. Marr, S. McGettigan, J. McPherson, T. Medina, N. Mohindra, A. Olszanski, O. Oluwole, S. Patel, P. Patil, S. Reddy, Mabel Ryder, B. Santomasso, S. Shofer, J. Sosman, Yinghong Wang, V. G. Zaha, M. Lyons, M. Dwyer, Lisa E Hang   +35 more
semanticscholar   +1 more source

Patient-centric trials for therapeutic development in precision oncology [PDF]

, 2015
An enhanced understanding of the molecular pathology of disease gained from genomic studies is facilitating the development of treatments that target discrete molecular subclasses of tumours.
A Hollebecque, A-M Tsimberidou, AD Barker, AL Tam, Andrew V. Biankin, AT Shaw, AV Biankin, B Zhang, C Le Tourneau, C Le Tourneau, C Lin, C Printz, CK Lee, CR Lindsay, D Cook, D Slamon, D Zardavas, DD Von Hoff, DE Gerber, DJ Sargent, DT Le, EA Eisenhauer, ED Green, ES Kim, F André, GD Demetri, GM Frampton, IR Watson, J Ledermann, J Lewin, J Verweij, JA Sosman, JY Douillard, L Chin, L Chin, L Seguin, LA Chantrill, LB Alexandrov, LJ Esserman, LJ Esserman, M Hay, M Maemondo, MG Kris, MR Stratton, MR Stratton, N Roper, N Waddell, NM Hylton, PA Jänne, PN Lara Jr, R Dienstmann, R Simon, RR Kalf, S Matsumoto, S Sleijfer, Simon J. Hollingsworth, SJ Dawson, SJ Mandrekar, Steven Piantadosi, TA Yap, TJ Hudson   +60 more
core   +1 more source

Chinese Expert Consensus on the Standardized Diagnosis and Treatment of 
Non‑small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations (2024 Edition)

Chinese Journal of Lung Cancer
The standard clinical practice of managing the non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations was elaborated in Chinese expert consensus on non‑small cell lung cancer with EGFR exon ...
Chinese Society of Clinical Oncology Non-small Cell Lung Cancer Committee
doaj   +1 more source